Pancreatic Cancer Clinical Trials 2026: KRAS Inhibitors, Immunotherapy, and New Treatments

Pancreatic cancer's 5-year survival has barely moved in decades — currently around 13% for all stages combined, primarily because over 80% of cases are diagnosed when surgical resection is no longer possible. The field spent 30 years watching every new approach fail: immunotherapy, antifibrotic agents, nab-paclitaxel combinations that improved median survival by weeks, not years. What's genuinely different in 2026 is KRAS. KRAS G12D — present in approximately 40% of pancreatic adenocarcinomas — was undruggable until recently. The KRAS G12C inhibitor story in lung cancer proved the target was druggable; the pancreatic cancer field waited for the chemistry to catch up on G12D. It has. Whether KRAS G12D inhibitors change survival outcomes remains to be demonstrated in Phase 3, but the Phase 1/2 signals are the most credible early efficacy data pancreatic oncology has seen in a long time.

Why Pancreatic Cancer Has Been So Hard to Treat

Three structural problems have defeated most treatment approaches for decades. First, PDAC presents late. The pancreas is retroperitoneal, symptoms are nonspecific (back pain, new-onset diabetes, weight loss), and there's no equivalent of the colonoscopy or mammogram to detect early disease in the general population. By the time most patients are diagnosed, the tumor has invaded locally or metastasized.

Second, the tumor stroma is extraordinarily dense. Pancreatic cancer is surrounded by a desmoplastic matrix of fibroblasts, collagen, and extracellular matrix components that physically limits drug delivery to tumor cells and excludes immune effector cells. Immunotherapy doesn't fail in pancreatic cancer because the immune system isn't trying — it fails because T cells can't reach the tumor.

Third, KRAS. KRAS mutations drive virtually every PDAC, and unlike in CRC or NSCLC, PDAC has no actionable minority: there's no EGFR-mutant subset, no ALK-rearranged cohort for which a targeted drug exists. Until KRAS itself became targetable, the entire tumor genetics of pancreatic cancer offered no precision medicine entry point.

KRAS G12D Inhibitors: Where the Phase 1/2 Evidence Stands

MRTX1133 (now being developed by Bristol-Myers Squibb following Mirati's acquisition) is the most advanced KRAS G12D-selective inhibitor in clinical development. Phase 1/2 NCT05737706 is enrolling patients with KRAS G12D-mutant solid tumors, with dedicated PDAC expansion cohorts. Early data presented at ASCO 2024 showed disease control (stable disease or partial response) in approximately 50% of evaluable PDAC patients as monotherapy — modest by many standards, but remarkable by pancreatic cancer standards where single-agent activity of any targeted drug has been essentially absent until now.

The combination strategy is probably where MRTX1133's real value will emerge. KRAS G12D inhibition combined with chemotherapy (gemcitabine + nab-paclitaxel), anti-PD-1, or anti-EGFR agents is the active development path, based on preclinical evidence of synergy and on the precedent from KRAS G12C inhibitor combinations in lung cancer. The AMPLIFY study is specifically examining MRTX1133 combinations in PDAC.

Pan-KRAS inhibitors offer an important alternative for patients without G12D specifically:

• RMC-6236 (Revolution Medicines): A RAS(ON) multi-selective inhibitor that targets multiple KRAS and NRAS mutations in their active (GTP-bound) state rather than a single mutation subtype. Phase 1/2 data in PDAC (NCT05379985) showed partial responses and durable stable disease in KRAS G12V, G12R, and other non-G12D mutations — covering patients excluded from G12D-selective trials.
• HRS-4642 (Heurigen, Phase 1): Oral KRAS G12D inhibitor with pancreatic cancer expansion cohorts; combination planning with gemcitabine scheduled for 2026 portion of the trial.

mRNA Personalized Cancer Vaccines: Phase 2 in PDAC

Moderna/Merck's mRNA-4157/V940 vaccine sequences each patient's tumor, identifies up to 34 patient-specific neoantigens, and manufactures a custom mRNA vaccine encoding those neoantigens — a process taking approximately 6–8 weeks. The treatment rationale is that pancreatic cancers, despite their low mutational burden, do present patient-specific neoantigens that an appropriately primed immune system can recognize.

The evidence base comes from two directions. In resected melanoma, KEYNOTE-942 showed mRNA-4157 + pembrolizumab reduced recurrence risk by 44% (HR 0.56) vs. pembrolizumab alone — a result robust enough to trigger FDA Breakthrough Therapy designation and Phase 3 initiation across multiple tumor types. In PDAC specifically, BioNTech's BNT122 (autogene cevumeran) Phase 2 IMCODE003 data showed that vaccine-induced neoantigen-specific T-cell responses predicted significantly longer recurrence-free survival in resected PDAC patients — HR 0.08 for responders vs. non-responders, a signal that drove Phase 2 expansion.

The mRNA-4157 PDAC program is evaluating the vaccine in the adjuvant setting (after surgical resection) combined with pembrolizumab and mFOLFIRINOX chemotherapy. The rationale for adjuvant timing: tumor tissue is available for sequencing, residual micrometastatic disease may be more vulnerable to immune surveillance, and the patient's immune system hasn't been compromised by extensive prior treatment. Enrollment requires sufficient tumor tissue from surgery — patients undergoing resection at participating NCI-designated cancer centers should ask about eligibility at the time of surgery planning.

CAR-T and Cellular Therapies: Early-Stage but Notable Progress

CAR-T has transformed blood cancers and faces a different problem in solid tumors: not target availability (mesothelin is highly expressed on PDAC cells and is a well-validated CAR-T target) but T-cell trafficking and persistence. The dense desmoplastic stroma physically blocks T-cell infiltration, and the immunosuppressive cytokine environment (TGF-beta, IL-10, VEGF) exhausts T cells that do penetrate.

The 2026 trials address this problem through engineering:

• Armored anti-mesothelin CAR-T: T cells engineered to secrete IL-15 or IL-21 within the tumor microenvironment to maintain their own survival and function despite immunosuppressive signals. Phase 1 trials ongoing at Memorial Sloan Kettering and MD Anderson.
• Anti-mesothelin CAR-T + checkpoint inhibitor: Combining T-cell delivery with anti-PD-1 to reduce exhaustion. Phase 1 data shows feasibility of manufacturing and infusion; tumor infiltration is being assessed by biopsy.
• TIL (Tumor-Infiltrating Lymphocyte) therapy: Lifileucel (Amtagvi), FDA-approved for melanoma in 2024, is being evaluated in PDAC. PDAC TIL expansion protocols are technically feasible but clinically complex given the immune-cold tumor microenvironment.

Chemotherapy Combinations and Standard-of-Care Backbone Trials

NALIRIFOX (liposomal irinotecan + oxaliplatin + fluorouracil + leucovorin) was FDA-approved in 2023 as first-line therapy for metastatic PDAC based on NAPOLI-3 showing median OS 11.1 months vs. 9.2 months with gemcitabine + nab-paclitaxel (HR 0.83). NALIRIFOX is now the comparator arm in several 2026 combination trials, including with anti-PD-1 (AMPLIFY-201) and with KRAS-targeted agents.

For the ~5–7% of PDAC patients with germline BRCA1/2 mutations, olaparib maintenance after first-line platinum-based chemotherapy is standard based on POLO trial data (median PFS 7.4 vs. 3.8 months, HR 0.53). Phase 2 trials are now combining olaparib with ATR inhibitors (ceralasertib) in BRCA-mutant PDAC to address acquired PARP inhibitor resistance, which develops rapidly in this setting.

Early Detection Trials: The Highest-Value Intervention

The single intervention with the most potential to change pancreatic cancer mortality is earlier diagnosis. At Stage IA (tumor confined to pancreas, ≤2 cm), 5-year survival is approximately 80%. At Stage IV (metastatic), it's approximately 3%. The challenge is detecting Stage IA — currently these tumors are almost exclusively found incidentally during imaging for other reasons.

• High-risk individual surveillance: CAPS (Cancer of the Pancreas Screening) consortium multi-center studies are tracking EUS and MRI/MRCP surveillance in individuals with BRCA2, PALB2, ATM, or CDKN2A mutations, or with familial pancreatic cancer (≥2 first-degree relatives). These observational studies are validating detection protocols, not testing drugs — but they represent the pathway to population screening programs.
• Liquid biopsy validation: The GRAIL Galleri multi-cancer early detection test is being validated in prospective trials including the NHS-Galleri study (140,000 UK participants). Pancreatic cancer is one of GRAIL's strongest ctDNA signals — PDAC sheds characteristic methylation patterns detectable in blood before clinical symptoms. Whether the sensitivity and specificity are sufficient for population screening at acceptable positive predictive value is what these trials determine.
• New-onset diabetes as a trigger: Approximately 50% of PDAC patients develop new-onset diabetes 6–36 months before cancer diagnosis (likely due to tumor-induced beta-cell dysfunction). CA19-9 measurement in patients with new-onset diabetes over 50 is being evaluated as a low-cost screening strategy that could identify PDAC before imaging-detectable disease.

How to Find Pancreatic Cancer Trials in 2026

• Get comprehensive molecular profiling first: Foundation One CDx or equivalent — confirming KRAS G12D vs. other KRAS subtypes, BRCA1/2, PALB2, ATM, NTRK fusions, MSI/TMB, and HER2. This is the prerequisite for meaningful trial matching. Many KRAS G12D inhibitor trials require confirmed G12D subtype — not just "KRAS mutant."
• Contact PanCAN Patient Services: The Pancreatic Cancer Action Network maintains the most comprehensive database of PDAC trials with direct coordinator relationships. Their patient services team provides free, personalized trial matching and can identify studies not yet widely publicized. pancan.org/clinical-trials.
• Seek consultation at an NCI-designated cancer center: Even if you receive primary care elsewhere, a consultation at an NCI-designated center (MD Anderson, Memorial Sloan Kettering, Johns Hopkins, Dana-Farber, UCSF) provides access to the most trials and the most experienced trial coordinators for PDAC-specific studies.
• Search ClinicalTrials.gov: Search "pancreatic cancer" + "recruiting" and filter by phase. Review the eligibility criteria for KRAS subtype requirements — not all PDAC trials accept all KRAS mutations.